Alectinib
- Generic Name
- Alectinib
- Brand Names
- Alecensa, Alecensaro
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N4O2
- CAS Number
- 1256580-46-7
- Unique Ingredient Identifier
- LIJ4CT1Z3Y
- Background
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ...
- Indication
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this ...
- Associated Conditions
- Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.